Bada 1989.

Study characteristics
Methods	Single‐centre randomized controlled trial
Participants	Inclusion criteria Birth weight <1 500 g; periventricular‐intraventricular haemorrhage <grade 1 at 1 hour Exclusion criteria Congenital malformations Thrombocytopenia Bleeding from puncture site or orifices Plasma creatinine level > than 1.8mg/dL
Interventions	Active intervention (n = 71) Prophylactic IV indomethacin 0.2 mg/kg at 6 hours of age; and 0.1 mg/kg at 18 hours and 30 hours of age Control (n = 70) IV placebo (no description available)
Outcomes	Relevant outcomes for this study included Death before hospital discharge IVH CLD (oxygen supplementation beyond 28 days) NEC (Bell stage 2 or 3 disease) Oliguria
Notes	Primary study location: Regional Medical Center, Memphis, Tenessee, USA Study period: not specified Trial registration: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	It was not stated how randomization was done
Allocation concealment (selection bias)	Unclear risk	No information provided on allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo was used suggesting personnel were blinded during the study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcome assessed by one investigator blinded to the allocation
Incomplete outcome data (attrition bias) All outcomes	Low risk	All randomized infants accounted for
Selective reporting (reporting bias)	Unclear risk	No protocol available for comparison
Other bias	Unclear risk	No specific issues noted.